Oral anti-hyperglycemic agents for the management of gestational diabetes mellitus.
The purpose of this review is to provide a brief overview for understanding the management guidelines of gestational diabetes. The rationale for the use of oral antidiabetic drugs is provided based on validation by appropriately conducted research trials. Concerns over teratogenicity due to possible placental transfer, neonatal and maternal outcome, and basic pharmacologic benefits are addressed.
Langer
Oded
O
Department of Obstetrics and Gynecology, St. Luke's-Roosevelt Hospital Center, Women's Health Service, University Hospital of Columbia University, 1000 10th Avenue, 10 C-01, New York, NY 10019, USA. odlanger@chpnet.org
D000284:Administration, Oral; D001645:Biguanides / Q000627:therapeutic use; D016640:Diabetes, Gestational / Q000188:drug therapy*; D005260:Female; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D011247:Pregnancy; D013453:Sulfonylurea Compounds / Q000627:therapeutic use; D045162:Thiazolidinediones / Q000627:therapeutic use
D001645:Biguanides; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D013453:Sulfonylurea Compounds; D045162:Thiazolidinediones